Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Matinas BioPharma Holdings, Inc. MTNB
$0.50
+$0.03 (5.78%)
На 15:31, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
102136273.00000000
-
week52high
0.94
-
week52low
0.39
-
Revenue
3188000
-
P/E TTM
-9
-
Beta
2.01868500
-
EPS
-0.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Aegis Capital | Buy | Buy | 13 авг 2020 г. |
| Piper Sandler | Overweight | 27 янв 2020 г. | |
| SunTrust Robinson Humphrey | Buy | 24 янв 2020 г. | |
| H.C. Wainwright | Buy | 26 июн 2019 г. | |
| BTIG Research | Buy | Buy | 17 мая 2019 г. |
| HC Wainwright & Co. | Buy | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Matkovits Theresa | A | 625000 | 625000 | 20 дек 2022 г. |
| Kucinski Keith A | A | 625000 | 625000 | 20 дек 2022 г. |
| Liu Hui | A | 625000 | 625000 | 20 дек 2022 г. |
| Jabbour Jerome D | A | 1988300 | 1988300 | 20 дек 2022 г. |
| Ferguson James J. III | A | 625000 | 625000 | 20 дек 2022 г. |
| Hoover Thomas | A | 475000 | 475000 | 20 дек 2022 г. |
| Corzo Kathryn Penkus | A | 142657 | 142657 | 14 ноя 2022 г. |
| Giordano Natasha | A | 142657 | 142657 | 14 ноя 2022 г. |
| Scibetta James S | A | 142657 | 142657 | 14 ноя 2022 г. |
| Ende Eric J | A | 142657 | 142657 | 14 ноя 2022 г. |
Новостная лента
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
GlobeNewsWire
11 мая 2023 г. в 07:30
BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern time. The conference is being held at the New York Hilton Midtown.
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
10 мая 2023 г. в 18:59
Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
GlobeNewsWire
03 мая 2023 г. в 07:00
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
7 Small-Cap Biotech Stocks with Massive Potential
InvestorPlace
27 апр 2023 г. в 18:36
While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript
Seeking Alpha
15 мар 2023 г. в 20:26
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Jody Cain - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Matkovits - Chief Development Officer Conference Call Participants Greg Fraser - Truist Securities Operator Greetings and welcome to the Matinas BioPharma 2022 Fourth Quarter and Full Year Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.